Bispecific Playgrounds? No, Factory Floors
Developers Prepare for Future Biologics Work by Exploring a Multitude of Antibody Formats
Vertex’s David Altshuler Humanizes Drug Discovery
Lessons from Vertex’s Small Molecule Drug Development Program for Cystic Fibrosis
In the mAb Race, Don’t Stumble at Characterization
Researchers Adapt Existing Techniques to Deal with Challenging New Monoclonal Antibodies
Bioprocessing Companies Push Limits of Upstream Technologies
Goal Is to Maximize Efficiency in Bioprocess Operations
For full access to this article login to GEN Select now.
Epigenetic-Derived Therapies on Horizon
Investigations Are Beginning to Elicit More Selective and Specific Druggable Targets
- How is the current model of drug discovery faring? “It’s not working,” stated Chas Bountra, Ph.D., chief scientist at the Structural Genomics Consortium (SGC) and professor of translational medicine, University of Oxford. “There are too many targets to choose from, and many of the targets being worked on today ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.